132 related articles for article (PubMed ID: 17186240)
21. The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies.
Robak P; Smolewski P; Robak T
Leuk Lymphoma; 2008 Aug; 49(8):1452-62. PubMed ID: 18608871
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of a patient with chronic lymphocytic leukaemia (CLL) presenting with bony metastases with aggressive antibody and chemotherapy.
Narayan H; Bandyopadhyay D; Schmidt K; Chachlani N; Hughes M; Paneesha S; Rose P; Borg A
Clin Lab Haematol; 2005 Dec; 27(6):405-8. PubMed ID: 16307545
[TBL] [Abstract][Full Text] [Related]
23. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL.
Klepfish A; Rachmilewitz EA; Kotsianidis I; Patchenko P; Schattner A
QJM; 2008 Sep; 101(9):737-40. PubMed ID: 18650226
[TBL] [Abstract][Full Text] [Related]
24. Bendamustine in the treatment of chronic lymphocytic leukemia.
Knauf W
Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.
Eichhorst BF; Busch R; Obwandner T; Kuhn-Hallek I; Herschbach P; Hallek M;
J Clin Oncol; 2007 May; 25(13):1722-31. PubMed ID: 17389338
[TBL] [Abstract][Full Text] [Related]
26. Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia.
Rogalinska M; Goralski P; Wozniak K; Bednarek JD; Blonski JZ; Robak T; Piekarski H; Hanausek M; Walaszek Z; Kilianska ZM
Leuk Res; 2009 Feb; 33(2):308-14. PubMed ID: 18676014
[TBL] [Abstract][Full Text] [Related]
27. Purine analogue-based chemotherapy regimens for second-line therapy in patients with chronic lymphocytic leukemia.
Lamanna N; Weiss MA
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S44-9. PubMed ID: 16549114
[TBL] [Abstract][Full Text] [Related]
28. A single unit lymphoma experience: outcome in a Cape Town academic centre.
Wood L; Robinson R; Gavine L; Juritz J; Jacobs P
Transfus Apher Sci; 2007 Aug; 37(1):93-102. PubMed ID: 17931976
[TBL] [Abstract][Full Text] [Related]
29. DNA repair and cellular resistance to alkylating agents in chronic lymphocytic leukemia.
Müller MR; Buschfort C; Thomale J; Lensing C; Rajewsky MF; Seeber S
Clin Cancer Res; 1997 Nov; 3(11):2055-61. PubMed ID: 9815597
[TBL] [Abstract][Full Text] [Related]
30. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
Willmore E; Elliott SL; Mainou-Fowler T; Summerfield GP; Jackson GH; O'Neill F; Lowe C; Carter A; Harris R; Pettitt AR; Cano-Soumillac C; Griffin RJ; Cowell IG; Austin CA; Durkacz BW
Clin Cancer Res; 2008 Jun; 14(12):3984-92. PubMed ID: 18559621
[TBL] [Abstract][Full Text] [Related]
31. Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines.
Larsson DE; Hassan S; Larsson R; Oberg K; Granberg D
Cancer Chemother Pharmacol; 2009 Dec; 65(1):5-12. PubMed ID: 19381631
[TBL] [Abstract][Full Text] [Related]
32. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group.
J Natl Cancer Inst; 1999 May; 91(10):861-8. PubMed ID: 10340906
[TBL] [Abstract][Full Text] [Related]
34. Clinical response to busramustine (KM-2210) in chronic lymphocytic leukemia: a pilot evaluation of estrogen receptor in relation to its therapeutic effect.
Nishikawa M; Uemura Y; Komada F; Ohno T; Katayama N; Shirakawa S
Jpn J Clin Oncol; 1988 Dec; 18(4):327-33. PubMed ID: 3204682
[TBL] [Abstract][Full Text] [Related]
35. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
36. Emerging therapy for chronic lymphocytic leukaemia.
Auer RL; Gribben J; Cotter FE
Br J Haematol; 2007 Dec; 139(5):635-44. PubMed ID: 17961187
[TBL] [Abstract][Full Text] [Related]
37. Pentostatin in chronic lymphocytic leukemia.
Sauter C; Lamanna N; Weiss MA
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1217-22. PubMed ID: 18721115
[TBL] [Abstract][Full Text] [Related]
38. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
Rigacci L; Mappa S; Nassi L; Alterini R; Carrai V; Bernardi F; Bosi A
Hematol Oncol; 2007 Dec; 25(4):198-203. PubMed ID: 17654614
[TBL] [Abstract][Full Text] [Related]
39. Primary cutaneous marginal zone B-cell lymphoma in a patient with chronic lymphocytic leukaemia.
Robak E; Jesionek-Kupnicka D; Robak T; Holub A; Wawrzyniak E; Bartkowiak J; Bednarek A; Constantinu M; Urbanska-Rys H
Br J Dermatol; 2007 Sep; 157(3):591-5. PubMed ID: 17697078
[TBL] [Abstract][Full Text] [Related]
40. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
